[ad_1]
Pfizer Inc said Wednesday that the final results of the late-stage trial of its COVID-19 vaccine showed it to be 95% effective, adding that it had the required two months of safety data and that it would request emergency clearance from the US. In a few days.
The final analysis comes just a week after the initial trial results showed the vaccine to be more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.
Market reaction: Equity markets strengthened slightly on the news. Europe’s STOXX 600 and US S&P 500 e-mini futures reached session highs. However, the movements were small compared to the jump after Pfizerprevious announcement. The reaction of European public debt and currencies was subdued.
Comments
Ian Jones, Professor of Virology, University of Reading
“The data is very strong … And it’s a good result when it comes to safety … He looks like a real contender.”
—Collected by Global Finance & Markets Breaking News team, Kate Kelland and Reuters health correspondents; Edited by Kirsten Donovan
[ad_2]
